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DNA methylation as a mediator of HLA-DRB1*15:01
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The human leukocyte antigen (HLA) haplotype DRB1*15:01 is the major risk factor for multiple
sclerosis (MS). Here, we ﬁnd that DRB1*15:01 is hypomethylated and predominantly
expressed in monocytes among carriers of DRB1*15:01. A differentially methylated region
(DMR) encompassing HLA-DRB1 exon 2 is particularly affected and displays methylation-
sensitive regulatory properties in vitro. Causal inference and Mendelian randomization pro-
vide evidence that HLA variants mediate risk for MS via changes in the HLA-DRB1 DMR that
modify HLA-DRB1 expression. Meta-analysis of 14,259 cases and 171,347 controls conﬁrms
that these variants confer risk from DRB1*15:01 and also identiﬁes a protective variant
(rs9267649, p < 3.32 × 10−8, odds ratio= 0.86) after conditioning for all MS-associated
variants in the region. rs9267649 is associated with increased DNA methylation at the HLA-
DRB1 DMR and reduced expression of HLA-DRB1, suggesting a modulation of the DRB1*15:01
effect. Our integrative approach provides insights into the molecular mechanisms of MS
susceptibility and suggests putative therapeutic strategies targeting a methylation-mediated
regulation of the major risk gene.
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Multiple sclerosis (MS), a leading cause of neurologicaldisability in young adults, is a chronic inﬂammatorydisease of the central nervous system (CNS) char-
acterized by autoimmune destruction of myelin and subsequent
loss of neurons. Although the exact cause of MS remains
unknown, inheritance of the disease is consistent with one locus
exerting a moderate effect and many loci with modest effects1.
The ﬁrst genetic risk factor was established more than 40 years
ago in the human leukocyte antigen (HLA) locus2, which encodes
molecules involved in key immune functions. The HLA genes are
among the most polymorphic genes and several alleles are often
inherited together in extended haplotypes due to extremely high
linkage disequilibrium (LD) in this part of the genome. The
extended haplotype of the HLA class II region (DRB5*01:01-
DRB1*15:01-DQA1*01:02-DQB1*06:02), which has been further
reﬁned to DRB5*01:01-DRB1*15:013–5, confers the strongest risk
for developing MS6. HLA class II locus encodes molecules
involved in presentation of peptide antigens to T cells by antigen
presenting cells (APCs) and DRB1*15:01 confers a 3-fold increased
risk of developing MS. With the advent of genome-wide associa-
tion studies (GWAS) more than 100 additional non-HLA loci
have been identiﬁed predisposing for MS with modest effects4,7–10.
However, the MS risk loci identiﬁed to date explain only about
half of the disease heritability8 and little is known about the
underlying causal variants and their molecular mechanisms.
Recent genetic and epigenetic ﬁne-mapping efforts suggest
that a vast majority of causal candidate variants for autoimmune
diseases are non-coding and likely play a role in regulating gene
expression11. Epigenetic mechanisms can regulate gene expres-
sion by modiﬁcation of DNA in a manner that is heritable
through cell divisions. The most studied epigenetic mechanism is
the covalent addition of a methyl group to cytosines in the context
of CpG dinucleotides, because of a known stable mechanism for
the propagation of mCpG by DNA (Cytosine-5)-Methyltransferase
1. Alterations in DNA methylation have been reported in blood,
CD4+, and CD8+ T cells as well as in pathology-free brain regions
from MS patients12–15. Recently, genetic variants in the loci
encoding epigenetic machinery genes have been associated with
MS suggesting a role for epigenetic mechanisms in disease
pathology9,16. However, while studies have investigated genetic
and epigenetic mechanisms independently, little focus has been on
how they may interact at a locus-speciﬁc level and jointly affect
susceptibility to MS. Indeed, a growing body of evidence suggests
that genetic and epigenetic modiﬁcations can interact
biologically17,18. This paradigm has been instrumental in deci-
phering the contribution of DNA methylation to the genetic risk
that predisposes to other complex diseases. Several studies suggest
that DNA methylation in the HLA class II region could mediate
genetic susceptibility to immune-mediated diseases such as
rheumatoid arthritis (RA)19, type 1 diabetes20, and food allergy21.
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Fig. 1 Study design and workﬂow diagram. MS: multiple sclerosis, HC: healthy controls, SNP: single nucleotide polymorphism, CIT: causal inference test,
eQTL: expression quantitative trait loci, NINDC: non-inﬂammatory neurological disease controls, SCAND: Scandinavia, SWE: Sweden, DE: Germany, ICE:
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In this study, we investigate DNA methylation in MS patients
in the context of genetic variation and gene expression with the
aim to decipher biological consequences of inheritance of MS risk
alleles and demonstrate that DNA methylation mediates risk of
developing MS. Speciﬁcally, DNA methylation in the HLA-DRB1
gene mediates the effect of the strongest MS risk variant HLA-
DRB1*15:01, and of a protective HLA variant (rs9267649) which
has not been previously reported, on HLA-DRB1 expression and
the risk of MS. Our results are summarized in Fig. 1.
Results
DRB1*15:01 is hypomethylated and predominantly expressed.
We conducted DNA methylation analysis in monocytes
sorted from MS patients and matched controls (n= 36, Fig. 1,
cohort 1, Supplementary Data 1) using Illumina Inﬁnium
HumanMethylation450 BeadChip arrays (450K arrays).
Monocytes are important precursors of tissue APCs22 and they
have been implicated in MS through their ability to present
myelin antigens, produce pro-inﬂammatory mediators, and
phagocytose myelin23–25. We identiﬁed two differentially
methylated regions (DMRs) that are associated with MS after
adjustment for confounders (FWER < 0.05) (Supplementary
Data 2). Both DMRs mapped to the HLA-DRB1 gene and com-
prised 19 consecutive CpGs, encompassing exon 2, which were
hypomethylated in MS patients (Fig. 2a). Since the DRB1*15:01
allele of the HLA-DRB1 gene confers the strongest risk for
developing MS, we analyzed methylation differences between
DRB1*15:01 carriers and non-carriers. Homozygous DRB1*15:01
carriers displayed signiﬁcantly lower DNA methylation levels at
HLA-DRB1 compared to heterozygous carriers and non-carriers
(Fig. 2b, Supplementary Data 2).
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Fig. 2 DRB1*15:01-associated DNA methylation in monocytes. a Differentially methylated CpGs using 450K arrays between multiple sclerosis (MS, n= 23,
red) cases and healthy controls (HC, n= 13, blue) comprising two signiﬁcant differentially methylated regions (Supplementary Data 2) in the HLA-DRB1
gene. b Differential methylation according to DRB1*15:01 haplotype: homozygous (+/+, n= 4, red), heterozygous (+/−, n= 11, orange), and non-carriers
(−/−, n= 20, blue) in MS and HC together (p-values from the additive model). All probes and p-values from other models are shown in Supplementary
Data 2. The horizontal gray bars indicate CpGs for which methylation has been validated using other methods (results depicted in c–e). c Replication using
pyrosequencing of three CpGs according to DRB1*15:01 haplotype: homozygous (+/+, n= 5, red), heterozygous (+/−, n= 17, orange), and non-carriers
(−/−, n= 27, blue) (p-values were generated using Kruskal–Wallis test). d Results from Sanger sequencing of bisulﬁte PCR clones for exon 2 region of
HLA-DRB1. Each line represents one read where black and white circles illustrate methylated and unmethylated CpGs, respectively (corresponding probes
ID from the 450K array annotation are included). e Methylation of cg06032479 of each allele from individuals heterozygous for DRB1*15:01 (n= 20, red
and blue colors representing DRB1*15:01 and the other allele, respectively) quantiﬁed by MSRE followed by allele-speciﬁc qPCR and tested using the
Mann–Whitney test (for n > 3 individuals/group). Individuals’ data are shown in Supplementary Fig. 1. a–c Data are presented as Tukey boxplots; *p < 0.05
**p < 0.01, ***p < 0.001
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04732-5 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:2397 | DOI: 10.1038/s41467-018-04732-5 | www.nature.com/naturecommunications 3
A potential bias in estimating DNA methylation with 450K
arrays can arise from the impact of single nucleotide polymorph-
isms (SNPs). This is of particular importance in the HLA region
due to its high density of polymorphic sites and the sequence
similarity between proximal HLA genes. To rule out the
possibility that low DNA methylation in DRB1*15:01 carriers
resulted from SNPs that abolish CpG sites or affect hybridization
of the probes, we used three different approaches (Fig. 2c–e). We
replicated 450K array ﬁndings using locus-speciﬁc
pyrosequencing of bisulﬁte converted (BS)-DNA for selected
CpGs for which robust assays could be designed (Fig. 2c, n= 49).
We further assessed DNA methylation by cloning and sequencing
single-strand BS-DNA from a larger segment encompassing exon
2 of HLA-DRB1. Sequencing results from ﬁve homozygous
DRB1*15:01 carriers conﬁrmed that the CpG sites are not
disrupted by local SNPs and that these CpGs preferentially exist
in an unmethylated state (Fig. 2d, only one carrier shown) in the
DRB1*15:01 carriers, compared to carriers of other haplotypes,
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e.g., DRB1*04 and DRB1*08. We also addressed allele-speciﬁc
methylation at cg06032479 using methyl-sensitive restriction
enzyme-qPCR (MSRE-qPCR) on genomic DNA in a subset of
DRB1*15:01 heterozygous individuals (haplotype-speciﬁc primers
were adapted from Olerup et al.26, see Methods and Supplemen-
tary Data 3). The DRB1*15:01 allele exhibited a lower cg06032479
methylation compared to other tested alleles (p= 7.9 × 10−3 and
p= 2.2 × 10−3 compared to DRB1*03 and DRB1*04, respectively,
Mann–Whitney test, Fig. 2e, the individuals’ data are shown in
Supplementary Fig. 1a). Taken together, these data demonstrate
speciﬁc hypomethylation of the DRB1*15:01 allele.
We next investigated potential functional consequences of
differential methylation at HLA-DRB1 in the same monocyte
cohort. To minimize any sequence-bias in ampliﬁcation, expres-
sion was quantiﬁed using four sets of primers mapping to less
polymorphic segments of the transcript (Supplementary Data 3).
HLA-DRB1 expression showed a strong negative correlation with
methylation at CpG sites in the region encompassing exon 2
(Fig. 3a) regardless of the primer pair used. Accordingly,
DRB1*15:01 carriers displayed signiﬁcantly higher expression of
HLA-DRB1 in monocytes compared to non-carriers (p= 1.1 × 10
−5 and p= 7.5 × 10−4 for homozygotes and heterozygotes vs.
non-carriers, respectively, ANOVA with Dunn’s multiple com-
parison test, n= 58, Fig. 3b). This suggests a functional link
between low DNA methylation and high HLA-DRB1 expression,
which was further supported by the increase in HLA-DRB1
expression in peripheral blood mononuclear cells (PBMCs)
treated with the demethylating drug 5-Aza-2′-deoxycytidine
(p= 0.036, ANOVA with Turkey’s multiple comparison test,
Fig. 3c). Using allele-speciﬁc primers, we quantiﬁed the expres-
sion of each HLA-DRB1 allele carried by individuals heterozygous
for DRB1*15:01. Compared to all other alleles, DRB1*15:01
displayed signiﬁcantly lower methylation (p= 3.9 × 10−9,
Mann–Whitney test, Fig. 3d, Supplementary Fig. 1a) and higher
expression (p= 5.4 × 10−7, t-test, Fig. 3e, Supplementary Fig. 1b).
Similar results were obtained using an allele-speciﬁc SNP analysis
approach (see Methods, Supplementary Fig. 1b). The allele-
speciﬁc analysis in monocytes from the same individuals showed
a negative correlation between methylation and expression
(Spearman r=−0.56, p= 1.7 × 10−3, Supplementary Fig. 1c).
As expected, global HLA-DRB1 levels correlated with the sum of
both alleles (Supplementary Fig. 1e), indicating that, for the
majority of tested haplotypes, high HLA-DRB1 expression in
monocytes reﬂects overexpression of the DRB1*15:01 allele.
We tested whether methylation in the region encompassing
exon 2 of DRB1*15:01 can exert regulatory properties on gene
expression. We addressed enhancer and promoter activity and the
effect of DNA methylation levels of the region using methylation-
sensitive CpG-free vector-based reporter systems. The inserts
were methylated using two different methyltransferases, SssI and
HhaI, which methylate all CpG sites (50 CpGs) or only the
internal cytosine residue in GCGC (5 CpGs), respectively.
Notably, the region encompassing exon 2 of DRB1*15:01
displayed signiﬁcantly decreased enhancer (p= 1.3 × 10−4) and
promoter (p= 9.7 × 10−3) activity if the insert was fully
methylated (ANOVA with Turkey’s multiple comparison test,
Fig. 3f, g, Supplementary Fig. 1f). This indicates that DNA
methylation is a regulatory feature of the region encompassing
exon 2 of DRB1*15:01 and that the hypomethylated DRB1*15:01
has a capacity to drive higher gene expression.
Although the size of the monocyte cohort was insufﬁcient for
formal methylation mediation analysis, our data suggest that
hypomethylation and predominant expression of DRB1*15:01
could be a mechanism by which DRB1*15:01 confers risk
of MS.
Genome-wide analysis of methylation mediation. Our ﬁndings
in monocytes suggest that DNA methylation may be an inter-
mediary of genetic risk in MS. Therefore, we set out to identify
the epigenetic marks that may mediate the genetic risk for MS by
integrating genome-wide genetic and epigenetic analysis, similar
to the original use of the Causal Inference Test (CIT) method in
our study on RA19 (Fig. 1). This method is robust to issues such
as pleiotropy and reverse confounding that are likely to occur in
complex diseases. Using whole blood samples from an indepen-
dent genotyped (500 K) MS case-control cohort (n= 279, cohort
2, Supplementary Data 1), analyzed with 450K arrays, we applied
the CIT method19 with genotype as a causal factor, DNA
methylation as a potential mediator and MS as the phenotypic
outcome (G, M, and Y, respectively, Fig. 4a). As regulatory
methylation changes generally encompass multiple CpGs, and to
minimize potential measurement errors, we sought to identify
DMRs27. We ﬁrst identiﬁed seven DMRs that associated with MS
after adjustment for confounders (FWER < 0.05), all of which
mapped to the HLA class II region (HLA-DRB5, -DRB1, -DQA1,
-DQB1 genes, Table 1). The methylation levels within these seven
DMRs were correlated in MS cases and healthy controls
(Supplementary Fig. 2), forming genetically controlled methyla-
tion clusters known as GeMes17. We found that these DMRs were
under the genetic control of 202 unique SNPs, with 875 sig-
niﬁcant SNP-DMR pairs (Bonferroni-adjusted p < 0.05), also
known as methylation Quantitative Trait Loci (meQTLs). Out of
the 202 SNPs, 52 were signiﬁcantly associated with MS status
(adjusted p < 0.05, maxT permutation), and all were located in the
HLA region. We ﬁnally performed CIT analysis to identify the
genetic variants that are independent of case/control status after
adjusting for DNA methylation, suggesting mediation (Fig. 4a).
Among the 52 SNPs, 50 were signiﬁcant after causal analysis
Fig. 3 DRB1*15:01-associated expression in monocytes. a Spearman correlation between DNA methylation at HLA-DRB1 (exon 2) (450K arrays) and HLA-
DRB1 expression quantiﬁed by RT-qPCR using primers targeting different segment of the transcript (exon 6 by primer sets 1 and 2, exon 1 by primer set 3,
and exon 4-6 by primer set 4). b HLA-DRB1 expression according to DRB1*15:01 haplotype: homozygous (+/+, n= 7, red), heterozygous (+/−, n= 21,
orange), and non-carriers (−/−, n= 30, blue) quantiﬁed by RT-qPCR (using primer set 1). c HLA-DRB1 expression (n= 4 independent experiments) in
PBMCs from DRB1*15:01 non-carriers treated with 5-Aza-2′-deoxycytidine (5-aza-dC). d HLA-DRB1 allele-speciﬁc methylation of cg06032474 quantiﬁed by
MSRE-qPCR from DRB1*15:01 heterozygote (+/−) individuals (n= 20, red and blue colors representing *15:01 and the other allele, respectively). e Relative
expression of each HLA-DRB1 allele from DRB1*15:01 heterozygote (+/−) individuals quantiﬁed by allele-speciﬁc qPCR (n= 26, red and blue colors
representing *15:01 and the other allele, respectively). Enhancer (f) and promoter (g) activity of the exon 2 region of DRB1*15:01 using CpG-free promoter-
containing (Lucia) and promoter-free (SEAP) reporter gene vectors, respectively. Constructs were partially or fully methylated using HhaI and SssI
enzymatic treatment, respectively. Results show relative activity (Lucia or SEAP normalized against Renilla) using ﬁve replicates in a representative
experiment performed at least 2–3 times. Efﬁciency of the in vitro methylation is shown in Supplementary Fig. 1f. NA not applicable due to absence of
promoter. b–g Data are presented as Tukey boxplots; *p < 0.05 **p < 0.01, ***p < 0.001, using Spearman test (a), ANOVA with Dunn’s (b), or Turkey’s
multiple comparison tests (c, f, g), the Mann–Whitney test (pooled alleles A vs. pooled alleles B) (d), and t-test (pooled alleles A vs. pooled alleles B) (e)
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using CIT (p < 0.05) including all seven DMRs (Table 1, Fig. 4b)
and thus represent potential methylation-mediated relationships
between SNPs and MS disease risk. The type of disease or
treatment status at sampling had no effect on the methylation
levels at any of the seven DMRs (p > 0.3 for all comparisons).
Results of the analysis are given in Supplementary Data 4 and one
example (chr6: 32552039-32552350; rs3135338) is illustrated in
Fig. 4c. We further replicated the methylation differences between
MS cases and controls for six out of the seven DMRs using sorted
CD14+ monocytes (n= 36, cohort 1), CD19+ B cells (n= 29), as
well as CD4+ (n= 33) and CD8+ (n= 29) T cells, with the least
pronounced differences being observed in CD8+ T cells (Fig. 4c,
Supplementary Data 5). Collectively, our data suggest a functional
link between DNA methylation at the HLA class II locus and the
risk of developing MS.
Remarkably, four of the seven DMRs reside within the HLA-
DRB1 gene and the two largest (DMR3 and DMR4) encompass
the same CpGs that we have identiﬁed as associated with HLA-
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DRB1 expression in monocytes. We addressed a potential
functional impact of the identiﬁed methylation-mediated SNPs
on the expression of HLA-DRB1 using RNA-seq data from
PBMCs28 (cohort 3, n= 156, Supplementary Data 1). We found
that the risk alleles of all genotyped SNPs (n= 34) were
associated with high HLA-DRB1 expression in PBMCs and the
risk alleles for 28 SNPs were also associated with low methylation
at DMR3 or DMR4 in blood (Supplementary Data 6). This
suggested a causal link between the identiﬁed SNPs, DNA
methylation at HLA-DRB1 exon 2 and HLA-DRB1 expression. To
address this, we employed a two-sample Mendelian randomiza-
tion (MR) using the SNPs previously identiﬁed as meQTLs for
DMR3 or DMR4 in the blood cohort and eQTLs for HLA-DRB1
in the PBMC cohort. We utilized the Egger’s regression slope
(βMR)29 to estimate the causal effect (see Methods). The MR-
Egger analysis revealed a signiﬁcant causal relationship between
DNA methylation at DMR3 (βMR ± SE=−1.92 ±0.33, p= 6.75 ×
10−9) or DMR4 (βMR ± SE=−1.80 ± 0.30, p= 3.04 × 10−9) and
HLA-DRB1 gene expression (Fig. 5 and Supplementary Data 6).
We also veriﬁed that the inferred causal direction is correct using
the MR Steiger test for directionality30. Namely, for the variant
with the strongest meQTL and eQTL effect (rs3132946), DNA
methylation was found to cause changes in HLA-DRB1 expres-
sion (p= 2.87 × 10−3 and p= 8.65 × 10−4 for DMR3 and DMR4,
respectively, Supplementary Fig. 3).
These ﬁndings provide additional insight into the molecular
mechanisms of variants in the HLA region that likely mediate the
risk for developing MS through changes in DNA methylation and
expression of HLA-DRB1.
Methylation mediation of DRB1*15:01 and a protective var-
iant. Considering the complex structure of the HLA locus, with
LD extending over large distances, and our ﬁndings of
DRB1*15:01-speciﬁc hypomethylation in monocytes, we investi-
gated whether the identiﬁed methylation-mediated SNPs confer
risk of MS independently of the DRB1*15:01 haplotype (Fig. 1).
We addressed this question in a large Scandinavian case-control
cohort (n= 8172 cases and 13,263 controls, cohort 4, Supple-
mentary Data 1) by testing association of the SNPs (45/50 with
genotype data) with MS after adjusting for DRB1*15:01 (and
associated terms) and all other established risk variants in the
HLA locus5 (Fig. 6a, Supplementary Data 7). The majority of
methylation-mediated SNPs (41/45) showed limited evidence of
association with MS (p ≥ 1 × 10−5) after conditioning on
DRB1*15:01 (Fig. 6a), suggesting that they confer risk from
DRB1*15:01. However, three methylation-mediated SNPs dis-
played suggestive association with MS (p < 1 × 10−5) after
adjusting for all known MS-associated variants in the HLA locus5
(Fig. 6a, Supplementary Data 7), suggesting potential novel var-
iants. We followed up these associations by performing a meta-
analysis using the Scandinavian cohort and three additional MS
case-control cohorts (Supplementary Data 1) from Sweden (n=
1418 cases and 1058 controls), Germany (n= 3934 cases and
8455 controls)9, and Iceland (n= 735 cases and 148,571 con-
trols), adjusting for all known MS-associated variants in the HLA
locus5 (Supplementary Data 7). rs9267649 displayed a genome-
wide signiﬁcant association with MS (p= 3.32 × 10−8, OR= 0.86)
with a similar protective effect in all cohorts (Fig. 6b). Three
additional methylation-mediated SNPs (rs2227956, rs2395182,
and rs9271640) exhibited suggestive association with MS (p < 1 ×
10−5) with rs2395182 and rs9271640 being in LD (r2= 0.72,
Supplementary Fig. 4). Among these suggestive SNPs, only
rs2227956 (p= 7.08 × 10−8, OR= 0.86) was in high LD with
rs9267649 (r2= 0.96, Supplementary Fig. 4), thus representing
the same association. Interestingly, the protective alleles at both
SNPs were associated with higher blood methylation levels at
DMR3 (chr6: 32551749-32551949) in exon 2 of the HLA-DRB1
gene and a lower HLA-DRB1 gene expression in PBMCs, parti-
cularly in DRB1*15:01 heterozygous individuals (Fig. 6c, d, Sup-
plementary Fig. 5). This suggests that the protective variant could
be counteracting the effect of the major DRB1*15:01 allele at the
molecular level.
Collectively, our ﬁndings strongly suggest that DNA methyla-
tion mediates the risk of DRB1*15:01 on MS. Moreover, we
identify an MS-associated variant which was not detectable by
conventional genetic studies and protects against MS potentially
via modulating DNA methylation at HLA-DRB1.
Discussion
Over the past decade, series of GWAS and custom-designed
arrays have steadily added more regions to the list of MS-
associated loci4,7–10. However, identiﬁcation and interpretation of
the causal variants remains difﬁcult and their mechanisms are still
largely unknown. Considering that the majority of susceptibility
loci reside in regulatory regions of the genome and the important
role of DNA methylation in gene regulation, we sought to
investigate DNA methylation in MS patients in the context of the
underlying genetic variation. Our data strongly suggest that DNA
methylation in the HLA class II locus, especially encompassing
exon 2 of the HLA-DRB1 gene, mediates the effect of DRB1*15:01
and of a protective HLA variant, which has not been previously
reported, on HLA-DRB1 expression and the risk of MS. These
ﬁndings provide new insights into the molecular mechanisms of
MS susceptibility and suggest alternative therapeutic strategies
based on modulating HLA-DRB1 levels.
Although the HLA region has been known as the strongest
genetic risk factor for MS for over 40 years, the exact causal gene
(s) and the mechanisms by which they affect MS susceptibility are
still elusive. It is generally accepted that disease-associated var-
iants in HLA-DRB1 primarily inﬂuence the structure of the
peptide-binding groove encoded by exon 2. Altered amino acid
residues of the HLA class II beta chain expressed on the APCs
could lead to a changed T cell repertoire that causes autoimmune
responses in the CNS31–34. However, speciﬁc antigens in MS have
Fig. 4 Genotype-dependent candidate DMRs that mediate genetic risk in multiple sclerosis (MS). a Summary workﬂow and results for identifying
epigenetically mediated genetic risk factors for MS. The diagrams on the right represent the relationships between genotype (G), DNA methylation (M),
and MS (phenotype, Y). Dashed lines, the association relationship; arrows, the causal relationship. b Association between candidate genetic risk-mediating
DMRs and genotype. Each dashed line represents a potential mediation relationship between an SNP and a DMR as determined by the CIT. c Association
between DNA methylation levels at DMR4 chr6:32552039-32552350 (located in exon 2 of HLA-DRB1) that mediates genetic risk in MS and phenotype
(top panels), with red and blue colors representing cases and controls, respectively, in blood cells (n= 279) (top left), and in sorted CD14+ monocytes
(n= 36), CD19+ B cells (n= 29), CD4+ (n= 33), and CD8+ (n= 29) T cells for cg08578320 (top right), or genotype rs3135338 (bottom left panel) with
blue, black, and red colors denoting AA, Aa, and aa genotypes. Bottom right panels: association between genotype (rs3135338) and phenotype and CIT.
Red horizontal bars mark percentage of cases for each genotype. Coefﬁcient (β) represents the dependence of the MS phenotype on genotype, with or
without adjusting for DNA methylation. The error bars represent the 95% conﬁdence interval for the coefﬁcient β. In the case of the methylation-mediated
model, the absolute value of the observed G:Y relationship strength reduces toward zero when adjusting for methylation. DMR: differentially methylated
region, SNP: single nucleotide polymorphism, CIT: causal inference test. The full list of SNP-DMR pairs is shown in Supplementary Data 4
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yet to be deﬁned35, which hinders the elucidation of the
mechanisms underlying susceptibility conferred by the major risk
haplotype DRB1*15:01, as well as development of antigen-speciﬁc
therapies. On the other hand, it appears that the structural theory
alone does not fully explain the association with MS, and recent
studies have suggested that association of DRB1*15:01 with MS
might also be related to gene expression28,36–38. Consistent with
this, we found that in monocytes of DRB1*15:01 carriers, HLA-
DRB1 is unmethylated and expressed at a higher level compared
to other haplotypes. We then utilized causal inference strategies
to test the hypothesis that DNA methylation mediates the effect
on HLA-DRB1 expression and, in turn, on MS susceptibility.
We ﬁrst applied CIT in a case-control GWAS cohort and
found statistical evidence of DNA methylation at HLA-DRB1
mediating the risk for MS from several SNPs located in the
extended HLA locus. The majority of these SNPs conferred the
effect from DRB1*15:01, as demonstrated by the lack of associa-
tion after conditioning on DRB1*15:01. The impact of the
DRB1*15:01 genotype on HLA-DRB1 methylation was similar in
MS patients and healthy controls (Supplementary Fig. 5). This
strong genetic effect can explain the observed methylation dif-
ferences between MS patients and controls in all studied cell
types, i.e., CD14+ monocytes, CD19+ B cells, CD4+ T cells, and
CD8+ T cells. Similar to our ﬁndings, HLA-DRB1 methylation
differences between MS patients and controls have been reported
in CD4+ T cells and suggested to be partially dependent on
DRB1*15:0112. Previous meQTLs studies have reported strong
genetic regulation of methylation at CpGs shared by the DMRs
identiﬁed in our study in white blood cells21, pancreatic islets20,
and brain samples39. Since these studies have not focused on
DRB1*15:01, we have investigated the SNPs underlying the
reported meQTLs and we found that many are in high LD with
DRB1*15:01 and show the same direction of effect as in our study.
It is thus not surprising that HLA-DRB1 methylation differences
between cases and controls exist in multiple cells types, although
the functional consequences of this genotype-driven methylation
likely differ between distinct cell types and depend on the
contribution of HLA class II molecules to a particular cell type-
speciﬁc function.
Most of the CpGs identiﬁed by CIT mapped to the same DMRs
in exon 2 of HLA-DRB1 found in monocytes, supporting a
functional link between genetic variation, methylation, expression
and risk of MS. Since DNA methylation changes can actively
impact gene expression or be a consequence of transcriptional
activity in the locus40, we further addressed the potential causal
effect of DNA methylation in exon 2 of HLA-DRB1 on expression
both experimentally and analytically. Using an in vitro reporter
system, we demonstrated that the exon 2 sequence of DRB1*15:01
exerts regulatory properties on gene expression in a DNA
methylation-dependent manner. This suggests that hypomethy-
lation of exon 2 could mediate the effect of DRB1*15:01 on HLA-
DRB1 gene expression. This is also supported by the signiﬁcant
causal relationship between methylation at DMRs in exon 2 and
HLA-DRB1 expression in PBMCs, obtained using two-sample
MR. The directionality of the causal relationship was further
conﬁrmed using a method that combines MR with a Steiger test
(MR-Steiger)30. Altogether, our data strongly support that
DRB1*15:01-dependent and DNA methylation-mediated levels of
expression, together with the structural characteristics of the
DRB1*15:01 molecule, contribute to MS risk. Indeed, both the
quantity and the quality of the peptide-HLA complexes
deﬁne immune responses41–43 and levels of the HLA genes in
humanized HLA and TCR transgenic mice inﬂuence the severity
of experimental MS-like disease44. Our ﬁndings highlight the
potential of using alternative or complementing strategies to
antigen-speciﬁc therapies in MS, which would reduce the
expression of HLA-DRB1. This strategy might be relevant beyond
MS, given the associations between genetic variants and DNA
methylation in the HLA class II region in several immune-
mediated diseases19–21.
The CpGs in exon 2 of HLA-DRB1 that mediate the effect on
MS risk belong to an intragenic CpG island that shows enrich-
ment for binding sites of the ‘architectural’ regulatory protein of
the genome CCCTC-binding factor (CTCF) (Table 1). A DNA
Table 1 DMRs that mediate genetic risk in multiple sclerosis
Probe DMR Location Nber
SNPs
FWERa Valuea Gene Description TFb Chromatin stateb
cg26981746 DMR 1 chr6:32490012-
32490043
47 0.013 0.12 HLA-DRB5 Intron 1/2 EZH2, ZNF263 Weak transcribed
cg12015991
cg13910785 DMR 2 chr6:32549849-
32549935
41 0 0.21 HLA-DRB1 Intron 2/3 POLR2A Transcriptional
elongationcg23905789
cg11404906 DMR 3 chr6:32551749-
32551949
41 0 −0.14 HLA-DRB1 Intron 2/3-
Exon 2
POLR2A,
ZNF263, SIN3A,
CTCF
Weak/poised promoter,
weak/poised enhancercg19575208
cg08845336
cg15568074
cg08578320 DMR 4 chr6:32552039-
32552350
42 0 −0.16 HLA-DRB1 Exon 2-Intron
1/2
POLR2A,
ZNF263, SIN3A,
CTCF
Weak/poised promoter,
weak/poised enhancercg09139047
cg15602423
cg15982117
cg16514085
cg14645244
cg00211215
cg09949906
cg24760581 DMR 5 chr6:32557970-
32558175
27 0 0.18 HLA-DRB1 TSS1500 YY1 Strong enhancer
cg10385522
cg24470466 DMR 6 chr6:32608858-
32608879
19 0.005 0.13 HLA-DQA1 Intron 1/2 POLR2A, CHD1 Weak promoter
cg17421046
cg13423887 DMR 7 chr6:32632694-
32632715
43 0.004 −0.13 HLA-DQB1 Exon 2 POLR2A, EZH2,
CHD1, CTCF
Active/poised promoter
cg05341252
DMR: differentially methylated region, chr: chromosome, Nber: number, SNP: single nucleotide polymorphism, FWER: family wise error rate, TSS: transcription starting site, TF: transcription factor
aMethylation vs. phenotype
bFrom ENCODE
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methylation-dependent role of intergenic CTCF has previously
been suggested in the gene-speciﬁc regulation of the HLA
class II locus45,46. Furthermore, an insulator function of intra-
genic CTCF has been reported when bound to intron 2 of
DRB1*0447. In line with this, non-canonical intragenic CTCF
occupancy has been shown to regulate intragenic chromatin
boundaries, ultimately affecting gene-speciﬁc transcription48,49
and alternative splicing50,51. However, whether differential
methylation at this locus affects binding of regulatory proteins
and ﬁne-tunes regulation of speciﬁc genes within the HLA locus
during disease development is yet to be explored.
In addition to the methylation-mediated SNPs that conferred
the effect from DRB1*15:01, we found potential associations with
MS that were independent of any known MS variant in the HLA
region5. A previously unreported protective variant was dis-
covered through signiﬁcant and highly suggestive association of
two SNPs in high LD (r2= 0.96), rs9267649 and rs2227956. Two
additional suggestive SNPs in high LD with each other (r2=
0.72), rs2395182 and rs9271640, were associated with the risk of
developing MS. The two latter SNPs do not necessarily represent
a variant that is independent of the signiﬁcant rs9267649 pro-
tective variant, as there is correlation between the SNPs (r2= 0.23
and r2= 0.22 for rs2395182 and rs9271640, respectively). In
contrast to the potent hypomethylation of DRB1*15:01, the
protective variant was associated with increased DNA methyla-
tion of DMR3 in exon 2 of HLA-DRB1 and with lower HLA-
DRB1 expression in PBMCs. Due to the strong inﬂuence of
DRB1*15:01 on methylation and expression levels and its corre-
lation with rs9267649 (r2= 0.40), the signiﬁcant functional
impact of the protective variant could only be observed in indi-
viduals stratiﬁed by DRB1*15:01 genotype, and it was particularly
evident in heterozygotes. This opposing effect suggests a putative
interaction with DRB1*15:01 and its potential to alter, possibly
antagonize, the effect of the major risk allele at the molecular
level. Interactions within the HLA region have previously been
suggested in immune-mediated diseases5,52. The protective var-
iant might inﬂuence HLA-DRB1 transcription through long-
range interactions between regulatory regions, as previously
suggested to occur within the HLA class II locus53. However,
given far-extending LD in the region, it is also plausible that the
associated SNP tags a true causal variant elsewhere in the HLA
locus, warranting future efforts to reﬁne this association.
Our ﬁndings highlight the importance of integrating genetic
and epigenetic data to explore molecular mechanisms underlying
causal variants and to identify variants that might escape detec-
tion by conventional genetic studies. Given the robust genetic
association of the HLA region with susceptibility to immune-
mediated diseases, our ﬁndings, together with other studies,
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suggest a role for DNA methylation in the pathogenesis of MS
and autoimmune diseases in general. This in turn opens new
avenues for development of therapeutic strategies aiming at
controlling immune reactions by modulating HLA protein levels.
Methods
Cohorts. Description of the cohorts is shown in the Supplementary Data 1. Brieﬂy,
all samples used for DNA methylation and expression studies in MS, i.e., peripheral
blood cells and sorted cells from blood, were collected in Sweden between 2005 and
2011. No formal sample size calculation was conducted, all available samples that
passed quality control have been included in all analyses. Cohort 1 consisted of
monocytes isolated from 62 MS patients and 20 healthy controls and was used for
genome-wide and locus-speciﬁc DNA methylation and expression analyses. Thirty-
six of them were selected for genome-wide analysis based on the sufﬁcient amount
of DNA required for 450K arrays and the matching clinical parameters (sex and
age) between the groups. Of the 23 MS patients, 91% (21/23) were not treated at
the time of sampling (either never treated or they stopped treatment at least
6 months before). All samples with DNA of sufﬁcient quantity (n= 49) were used
for pyrosequencing validation. All samples with available RNA of sufﬁcient quality
(n= 58) were used for qPCR-based gene expression analysis. All samples that were
DRB1*15:01 heterozygotes and where DNA/RNA of a sufﬁcient quantity and
quality was available, were used for allele-speciﬁc methylation and expression
analyses. Details of individuals used in speciﬁc analyses are provided in the Sup-
plementary Data 1. Cohort 2 used for CIT analysis on peripheral blood cells
included 140 MS patients with relapsing-remitting (RRMS, n= 121), primary
progressive (PPMS, n= 4), or secondary progressive (SPMS, n= 15) disease, and
139 healthy controls. In total, 65% (91/140) of MS patients were treated at the time
of sampling but the majority, 85% (77/91), received drugs that have a moderate
impact on disease activity (e.g., 63 received interferon beta preparations and 12
Glatiramer acetate). Cohort 3 used for expression QTL analysis comprised PBMCs
from 156 patients, including 21 clinically isolated syndrome (CIS), 105 MS patients,
and 30 non-inﬂammatory neurological disease controls (NINDC), such as neur-
algia, paresthesia, sensory symptoms, vertigo, tension headache28. Cohort 4 com-
prised four non-overlapping case-control cohorts used for conditional association
studies. The Scandinavian (SCAND) cohort consisted of 8172 MS cases and 13,263
controls from the three Swedish national studies of MS; EIMS54, GEMS55, and
IMSE56. In addition, cases were included from a local biobank of MS cases as well
as a cohort of Swedish blood donors57 and Swedish controls from the OLIVIA58,
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SASBAC59, and Twingene60 studies. Danish cases and Norwegian cases and con-
trols from in the IMSGC WTCCC2 GWAs were also included in the SCAND
cohort4. The Swedish (SWE) cohort consisted of additional MS cases (n= 1418)
and controls (n= 1058) from Sweden. The German (DE) cohort comprised
MS cases (n= 3934) recruited from multiple sites in Germany9 and matched
controls (n= 8455) from several population-based cohorts across Germany namely
KORA61, HNR62, SHIP63, DOGS64, and FoCus65, as previously described9. The
Icelandic (ICE) cohort consisted of 735 MS cases diagnosed between 1950 and 2005
and followed up at Landspitali, the National University Hospital of Iceland10 and
148,571 population-based controls available through on-going projects at deCODE
genetics. The study was approved by the National Bioethics Committee of Iceland
(VSN_15-212) and conducted in agreement with conditions issued by the Icelandic
Data Protection Authority (DPA). All subjects who donated DNA samples signed
informed consent. Personal identiﬁers of the patient data and biological samples
were encrypted by a third party system approved and monitored by the DPA. An
additional 333 healthy individuals with genotype and 450K array data have been
obtained from the EIRA (the Epidemiological Investigation of Rheumatoid
Arthritis) cohort from Sweden, GSE4286119. All study participants had given their
informed consent according to ethical board approval. Speciﬁcally, the study
complies with ethical regulations and was approved by the Regional Ethical Board
at Karolinska Institutet (Solna, Sweden), Copenhagen and Fredriksberg, (Den-
mark), Oslo (Norway) and Icelandic national bioethics committee (VSN 15-212).
For the German cohorts, the local ethics committees of the individual institutions
contributing patients provided positive votes for each local study (Germany):
Technical University Munich, Max Planck Institute of Psychiatry Munich
(approved by the ethics committee of the Medical Faculty at the Ludwig Max-
imilians University, Munich), University of Münster, University Medical Center of
the Johannes Gutenberg University Mainz (approved by the ethics committee of
the medical association of Rheinland-Pfalz with the approval ID 837.019.10(7028)),
Ruhr-Universität Bochum (reg. nr. 4319 12), University Medical Center Hamburg-
Eppendorf (approved by the ethics committee of the Ärztekammer Hamburg),
Charité—Universitätsmedizin Berlin, University of Rostock, University of Heidel-
berg, University of Marburg, and University of Leipzig.
Sample preparation. PBMCs were obtained from 50 ml of blood and extracted
using standard Ficoll gradient procedures directly after collection. Monocytes were
isolated using CD14+ positive selection on MACS microbeads magnetic separation
(Miltenyi), according to manufacturer’s instructions (>95% purity). Sorting of the
CD4+ and CD8+ T cell and CD19+ B cell populations was performed from the
negative fraction obtained after sorting of monocytes by adding ﬂuorochrome
conjugated antibodies against human CD4 (clone SK3, APC-conjugated, Becton
Dickinson), CD8 (clone SK1, FITC-conjugated, Becton Dickinson), CD3 (clone
UCHT1, PE-conjugated, BD Bioscience), and CD19 (clone SJ25C1, APC-Cy7-
conjugated, Becton Dickinson) using high speed MoFlo™ cell sorter with >99%
purity (Beckman Coulter, Inc). Extraction of genomic DNA and RNA from sorted
cells was performed using Gen Elute Mammalian Genomic DNA Miniprep kit
(Sigma-Aldrich) and RNeasy Mini kit (Qiagen), respectively. The amount and
quality of DNA/RNA was accessed with a NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies Inc). Processing of samples for 450K arrays was done at
BEA core facility, Karolinska Institutet (Stockholm) for monocytes and CD4+
T cells, and at Johns Hopkins University School of Medicine (Baltimore) for whole
blood, CD8+ T cells and CD19+ B cells. For each experiment, MS cases and
controls were randomized and technicians performing the genotyping, RNA-seq
and 450K arrays were blinded to the MS disease status during the experiments.
For ex vivo PBMCs culture, PBMCs from non-carrier individuals of
DRB1*15:01 risk haplotype were cultured in Roswell Park Memorial Institute
(RPMI) medium supplemented with 10% fetal bovine serum, 1% penicillin/
streptomycin, 2 mM L-Glutamine, and 1 mM sodium pyruvate at 37 °C in 5% CO2.
Cells were stimulated with phorbol 12-myristate 13-acetate (PMA, Sigma) and
exposed to different doses (0.5 µM, 5 µM) of 5-Aza-2′-deoxycytidine (Sigma) for
3 days prior to harvesting and subsequent RNA/DNA extraction using AllPrep
DNA/RNA Micro Kit (Qiagen).
Expression analyses of HLA-DRB1 in monocytes. The full list of primer
sequences used in this study is shown in Supplementary Data 3. Expression of
HLA-DRB1 was quantiﬁed using primers targeting different segments (exon 1,
exon 4–6, and exon 6) of the transcript. Allele-speciﬁc expression analysis of HLA-
DRB1 variants was assessed using primer sets mapping to exon 2 of the transcript
and speciﬁc for each group of alleles (targeting multiple haplotype-speciﬁc SNPs,
adapted from Olerup et al.26 and conﬁrmed using in silico alignment to IPD-
IMGT/HLA database). Similar allele-dependent expression results were obtained
by applying a single SNP-based approach targeting rs9270303 using two allele-
speciﬁc forward primers speciﬁc for either DRB1*15:01/*01 or the other HLA-
DRB1 alleles (*03–*14), and one common reverse primer. Real-time PCR was
performed on a BioRad CFX384/C1000 Real-Time Detection System with a three-
step PCR protocol using SYBR green ﬂuorophore: 95 °C:3 min, followed by 40
cycles of 95 °C:10 s, 60 °C (65 °C for the allele-speciﬁc SNP-based ampliﬁcation):
30 s and 72 °C:30 s. Relative quantiﬁcation of mRNA levels was performed using
the standard curve method, with ampliﬁcation of target mRNA and endogenous
control Actin mRNA. Assumption of equal variance between groups was tested
using Brown-Forsythe test. Differences in HLA-DRB1 levels between DRB1*15:01
homozygotes, heterozygotes and non-carriers, and after of 5-Aza-2′-deoxycytidine
were tested using ANOVA with Dunn’s and Turkey’s multiple comparison tests,
respectively. DRB1*15:01 expression was compared to expression of the other allele
in DRB1*15:01 heterozygotes using t-test. Correlation between HLA-DRB1 levels
and methylation at HLA-DRB1-associated CpGs generated with 450K arrays was
performed using the Spearman test. All statistical analyses were performed in
GraphPad Prism 6 and 7 (GraphPad Software).
Methylation analyses of HLA-DRB1 in monocytes. For pyrosequencing and
cloning-sequencing, 500 ng of genomic DNA from each sample was bisulﬁte-
converted using an EZ DNA methylation Kit (ZYMO research).
A subset of CpGs exhibiting robust pyrosequencing assays (cg09949906,
cg11993350, cg24071943) were selected for pyrosequencing validation. Primers
were designed using PyroMark Design software (Qiagen) (Supplementary Data 3).
A ﬁrst run of pre-PCR was necessary to amplify the region including cg11993350,
cg24071943 (“PCR_out”, Supplementary Data 3). One microliter of BS-DNA (~10
ng) was applied as a template in the PCRs performed with the PyroMark PCR kit
(Qiagen) using 5′-biotinylated reverse primers. The entire PCR product, 4 pmol of
the respective sequencing primer, and streptavidin sepharose high-performance
beads (GR Healthcare), were used for pyrosequencing on the PSQ 96 system and
PyroMark Gold 96 reagent kit (Qiagen). The PyroMark CpG software 1.0.11
(Qiagen) served for data analysis. Assumption of equal variance between groups
was tested using Brown-Forsythe test. Differences in methylation levels between
DRB1*15:01 homozygotes, heterozygotes and non-carriers were tested using
Kruskal-Wallis test with Dunn’s multiple comparison test in GraphPad Prism 6.
A larger fragment including exon 2 of HLA-DRB1 was selected to further
validate methylation differences. Knowing that this locus represents a CpG rich
region and that bisulﬁte conversion results in a fragmentation of the DNA,
ampliﬁcation of the ﬁnal product (~675 bp comprising 43 CpGs, 16 of them being
annotated in the 450K array) required a 3-step nested-PCR protocol using
SupraTherm Taq (GeneCraft, Germany) and the primers listed in Supplementary
Data 3. The last PCR primers contain HindIII and EcoRI restriction enzyme motifs
to allow subsequent cloning. The ﬁrst 2 PCRs (PCR_A, Supplementary Data 3)
were conducted according to speciﬁc cycle parameters66 and all PCR products were
diluted 1:100 prior to next PCR. After gel excision and extraction of the target band
using a gel extraction kit (Qiagen), the exon 2 of HLA-DRB1 was cloned into the
pcDNA3.1 vector using DH5α competent cells (One Shot® MAX Efﬁciency®
DH5α™-T1R, Life Technologies). Positive clones were veriﬁed by PCR and by
restriction enzyme digestion and the plasmids were sent for sequencing (Euroﬁns
MWG Operon, Germany). Sequence alignment was performed with Vector NTI
software (InforMax).
Individual CpG allele-speciﬁc DNA methylation assessment was performed
using methyl-sensitive restriction enzyme-qPCR (MSRE-qPCR). The CpG
methylation-sensitive digestion of genomic DNA was carried out with the EpiJET
DNA Methylation Analysis Kit based on MspI/HpaII digestion (ThermoScientiﬁc)
using 30 ng of genomic DNA. Brieﬂy, HpaII cuts only unmethylated CCGG motif
from cg0603247 whereas MspI cut both unmethylated and methylated CCGG
equally. The allele-speciﬁc methylation levels were quantiﬁed using the
aforementioned allele-speciﬁc primers-qPCR and the 2-ΔCt method and expressed
as the ratio between HpaII-digested DNA (target) and input/non-digested DNA
(reference) used for enzymatic reaction. DRB1*15:01 methylation was compared to
methylation of the other allele in DRB1*15:01 heterozygotes using the
Mann–Whitney test in GraphPad Prism 6.
Investigation of the regulatory properties of the identiﬁed DMR was conducted
using in vitro DNA methylation reporter assays. A fragment, including exon 2 of
DRB1*15:01 and the regions upstream and downstream of exon 2 (1133 bp), was
ampliﬁed using speciﬁc primers (Supplementary Data 3), containing AvrII or SpeI
sites. PCR-ampliﬁed products were cloned into pCpG-free promoter vector
(Invivogen) containing a Lucia luciferase reporter gene and into a pCpG-free basic
vector (Invivogen) containing a murine secreted embryonic alkaline phosphatase
(mSEAP) reporter gene. In order to address the impact of DNA methylation on the
reporter gene expression, all constructs were either completely methylated (50 CpG
sites) or partly methylated (methylation of internal cytosine residues in the GCGC
sequence, 5 CpG sites) by incubation with either SssI or HhaI methyltransferases,
respectively (New England BioLabs). The control condition (mock-methylated)
was treated equally, but in absence of any methyltransferase, and corresponds to
the hypomethylated DRB1*15:01 sequence. Methylated and mock-methylated
constructs were puriﬁed using a QIAquick PCR puriﬁcation Kit (Qiagen). The
completeness of methylation was checked using an EpiJET DNA Methylation
analysis Kit (MspI/HpaII) (ThermoFisher Scientiﬁc), followed by gel
electrophoresis (Supplementary Fig. 1f). Original insert-empty Lucia and SEAP
vectors completely, partly and mock-methylated were used as controls. For reporter
gene expression assay, Human embryonic kidney HEK293T cells (kindly provided
by A. Espinosa’s lab, Karolinska Institutet, Sweden) were cultured as PBMCs but in
Dulbecco’s Modiﬁed Eagle’s medium. Cell line authentication was not tested as
they were used to study the effect of exogenous transfected DNA. Mycoplasma
contamination was not tested. In a 96-well plate, 100 ng of constructs were co-
transfected with 5-10 ng of the control vector pGL4-TK-hH Luc constitutively
expressing Renilla luciferase using Effectene Transfection Reagent (Qiagen). Lucia,
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SEAP and Renilla luciferase activity were measured after 48 h using QUANTI-Luc
(Invivogen), the Phospha-Light System (Applied Biosystems) and the Dual-Glo
Luciferase Assay System (Promega), respectively, according to manufacturer’s
instructions, on the GloMax 96 Microplate Luminometer (Promega). Direct or
inverted orientation of the sequence yielded similar results. Results are expressed as
relative activity (Lucia or SEAP normalized against Renilla) and represent the mean
value of ﬁve replicates in a representative experiment replicated at least 2–3 times.
Assumption of equal variance between groups was tested using Brown-Forsythe
test. Statistical analyses were performed using ANOVA with Turkey’s multiple
comparison test in GraphPad Prism 7.
Genome-wide DNA methylation analysis in monocytes. We estimated the
methylation level in sorted cells as the ratio between the methylated signal and the
sum of methylated and unmethylated signals67. We ﬁltered probes that (i) contain
known common SNPs outside HLA, (ii) are located on the X and Y chromosomes
and (iii) with detection p-values larger than 0.01. The sorted cell types were con-
ﬁrmed using the estimateCellCounts function from the minﬁ package27. To pre-
process raw beta values before differential methylation analysis, we used the 3-step
pipeline considered as optimal in Marabita et al.67: quantile normalization and
Beta Mixture Quantile dilation67. Normalization with ComBat from the SVA
package was used to correct for slide effects as identiﬁed using PCA68. Batch cor-
rected beta values and Limma (Linear Models for Microarray Data)69 were used to
compute differential methylation. The linear model included age, sex, and disease
stage (RRMS and SPMS) as covariates. DMR analysis was carried out using the
Bumphunter package and included the same model of age, sex, and disease stage
(RRMS and SPMS) as covariates. All HLA-DRB1-associated CpGs were subsequently
tested for association with the DRB1*15:01 genotype using additive, dominant and
recessive models and correcting for sex, age, and status (HC, RRMS, or SPMS).
Methylation mediation analysis in peripheral blood. The methylation data from
450K arrays was preprocessed using the Illumina default procedure implemented in
the Bioconductor minﬁ package27. The probe level raw data for each sample were
normalized using Illumina’s control probe scaling procedure and converted to
methylation values on the 0–1 scale (M/(M+U+ 100), where M and U represent
the methylated and unmethylated signal intensities, respectively). For DMR analysis
(collapsed CpGs analysis), we averaged measurements from CpG islands, shores,
and shelves into one value for each sample using the cpgCollapse function in minﬁ
package27. These collapsed methylation measurements were then used
for genotype-dependent DMR identiﬁcation and CIT analysis, as we did previously
in the single CpG analyses19. All analyses were performed in R 2.14 and
Bioconductor 2.9.
Cell counts for the six major cell types in blood (Granulocytes, B cells, CD4+
T cells, CD8+ T cells, monocytes, and NK cells) for each individual were estimated
using the estimateCellCounts function in minﬁ package27, which obtain
sample-speciﬁc estimates of cell proportions based on reference information
on cell-speciﬁc methylation signatures70.
To identify the DMRs associated with the MS phenotype, we used the
bumphunter function in minﬁ package27 with adjustment for confounders: age,
sex, self-reported smoking status (ever smokers vs. never smokers), hybridization
date, and the ﬁrst two principle components of estimated differential cell counts.
Regions, that have a family wise error rate (FWER) less than 0.05 with 1000
resamples and contain at least 2 probes, were identiﬁed as MS-associated DMRs.
To evaluate the effect of the type of disease (RRMS, PPMS, and SPMS) or treatment
at sampling (MS without treatments, MS with treatment) on DNA methylation at
identiﬁed DMRs, the differences of group means were tested using either an
ANOVA test (for the type of disease), or Student’s t-test (for treatment).
To identify genotype-dependent DMRs and CIT analysis, all MS-associated
DMRs were subsequently tested for association with genotype (594,262 SNPs)
using an additive minor-allele dosage model. Genotype-DMR associations were
corrected for multiple testing using a stringent Bonferroni-adjusted threshold of
0.05 (7 DMRs × 594,262 SNPs)= 1.20 × 10-8. Brieﬂy, each of the genotype (SNP)-
methylation (DMR)-phenotype (MS) relationships was assessed using the CIT71 to
classify them as methylation mediated, methylation consequential, and
independent. Because the CIT was designed for continuous phenotypes rather than
case-control studies, we used a modiﬁed version based on logistic regression19.
Expression analysis from RNA-seq in PBMCs. RNA was extracted from PBMCs
from individuals that had been genotyped on the ImmunoChip and diagnosed with
either MS, CIS or NINDs. Library preparation was conducted for samples that
passed the criteria of sufﬁcient amount, concentration, and quality (>of RNA. A
total number of 17 samples were later discarded after quality control of sequencing
data. A ﬁnal number of 156 samples were included, after matching with genotype
data from the same individuals (cohort 3, Supplementary Data 1). cDNA libraries
for sequencing were prepared using Illumina TruSeq kit (Illumina, San Diego,
USA) and sequenced on an Illumina HiSeq 2000 machine. We generated data in
fastq format using Illumina 1.8 quality scores. We obtained paired-end reads with a
length of 100 bp from all 156 samples on an average sequence depth of 36 million
reads per sample. The reads were mapped to the H. Sapiens reference genome
(NCBI v37, hg19) using STAR aligner. Conditional Quantile Normalization (CQN)
method was used to normalize the count datasets and to account for the GC
content bias. The residuals obtained after correcting for batch-effect and disease-
type using lmFit and eBayes from limma package69 on CQN values is used to
correlate MS risk genotypes obtained from Illumina immunochip8 and Human660-
Quad chips4. eQTLs were identiﬁed using a linear additive risk allele dosage model
and the residual gene expression values for HLA-DRB1.
Mendelian randomization. To test the hypothesis that DNA methylation causes
changes in gene expression, we exploited a two-sample MR framework. For 42
SNPs that signiﬁcantly (p ≤ 5.86 × 10−9) associated with DNA methylation at
DMR3 and DMR4 and signiﬁcantly (p < 0.05) mediated the effect of the genetic
risk of MS using the CIT, we extracted the exposure summary statistics (effect size,
standard error, sample size, p-value) from the linear regression analysis on cohort 2
(blood) using an additive minor allele dosage model. We obtained the corre-
sponding outcome summary statistics from the HLA-DRB1 eQTLs considered in
cohort 3 (PBMC), using an additive risk allele dosage model. The MR analysis was
performed using the TwoSampleMR30 and MendelianRandomization R libraries.
We ﬁrstly clumped the meQTL SNPs by removing the SNPs in strong LD (R2 >
0.8 in 10,000 kb window) and then we retrieved the corresponding eQTL SNPs and
associated summary statistics. We harmonized the effects of the SNP on the out-
come and the exposure by ensuring that they refer to the same allele, correcting the
strand for non-palindromic SNPs, and dropping all palindromic SNPs from the
analysis. We then retrieved an LD correlation matrix from the MR-base database
(~500 Europeans in 1000 genomes data)30 and performed MR Egger regression
accounting for the correlation between variants. This method is valid under the
assumption that the associations of the genetic variants with the exposure are
independent of the direct effect of the genetic variants on the outcome, and it
allows us to obtain a consistent causal effect estimate as the slope from the Egger
regression, as explained in Bowden et al.29. Noteworthy, there was no evidence of a
directional pleiotropic effect (p= 0.37 and 0.41 for DMR3 and DMR4, respectively)
or heterogeneity (Cochran’s Q statistic, p= 0.34 and 0.57 for DMR3 and DMR4,
respectively). As the method considers that all the variants must be orientated such
as the associations with the exposure have the same (positive) sign, we set all the
associations with the exposures to be positive and the associations with the out-
come were re-oriented. The MR Steiger test for directionality was considered for
assessing the correct direction of causality30, for the variant with the strongest
meQTL and eQTL effect (rs3132946). Brieﬂy, this method performs the Steiger test
to orient the direction of causality and explores a range of potential values of
measurement error in the exposure and the outcome, to assess how reliable the
inference of the causal direction is and gives a reliability ratio (R) for sensitivity
analyses. The calculated R= 6.5 and R= 7.9 for DMR3 and DMR4, respectively
(Supplementary Fig. 3), means that it is R times more likely that the inferred
direction of causality is correct (i.e., DNA methylation causes gene expression)
compared to the opposite direction (gene expression causes methylation).
Regression analyses. We ﬁt linear regression model with the methylation at each
DMR, generated by CIT analysis in blood (cohort 2), as the outcome and the
following predictors: SNP (rs9267649 or rs2227956), age, sex, self-reported
smoking status (ever smokers vs. never smokers), batch, status (MS, HC), and the
ﬁrst two principle components of estimated differential cell counts in DRB1*15:01
homozygotes, heterozygotes, and non-carriers separately. Analysis was performed
on 279 individuals from cohort 2 and additional 333 healthy individuals from the
EIRA cohort. We ﬁt linear regression model with the HLA-DRB1 expression value
in PBMCs (cohort 3) as the outcome and the following predictors: SNP (rs9267649
or rs2227956), batch and status (MS, CIS, NINDC) in DRB1*15:01 homozygotes,
heterozygotes, and non-carriers separately. All analyses were done in Rcmd.
Conditional association analyses and meta-analysis. Genotyping for the dif-
ferent samples in the SCAND cohort was carried out using different Illumina
genotyping chips and quality control was carried out for each cohort separately.
The genotyping and basic quality control for the Norwegian and Danish cohort
(n=1362) as well as 648 of the Swedish MS cases and controls has been carried out
by IMSGC4. 12,479 of the Swedish cases and controls were genotyped using the
Illumina OmniExpress bead chip by deCODE. The TwinGene cohort (n= 6748)
was genotyped with Illumina OmniExpress bead chip at the SNP&SEQ Technology
Platform Uppsala, and only one individual in each twin pair was included in
subsequent analysis. Genotypes from ancestry informative markers from all the
autosomes (n= 3062) were combined and used for identifying related individuals
(n= 1335) using the genome command in PLINK v1.9 in a combined analysis of
all the cohorts72. Population outliers identiﬁed using the SmartPCA program with
standard settings (n= 199) were removed73. Four principal component vectors
were signiﬁcant in the remaining individuals and were used for controlling
population stratiﬁcation.
Genotypes in the HLA region were used to impute HLA genotypes using
HLA*IMPv274. Since genotypes for all DNA methylation-mediated CIT SNPs were
not available, we replaced the missing SNPs with SNPs in high LD in the 1,000
Genomes study in the European population [http://browser.1000genomes.org/
index.html]. The association of CIT markers conditional on established HLA MS
risk alleles5 and four principal component vectors was performed using the GLM
command in R3.3.3. The established MS risk HLA model used contained the
following terms: DRB1*15:01 presence, DRB1*15:01 homozygotes, DRB1*13:03
presence, DRB1*03:01 presence, DRB1*03:01 homozygotes, DRB1*08:01 presence,
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DQB1*03:02 presence, DQA1*01:01 presence, DQB1*03:01 presence, A*02:01
presence, A*02:01 homozygotes, B*44:02 presence, B*38:01 presence, B*55:01
presence, two SNPs in the HLA region (rs2229092 and rs9277565, in both cases
presence of minor allele) as well as interaction terms between presence of
DRB1*15:01 and DQA1*01:01 and presence of DQB1*03:02 and DQB1*03:01. In
analyses conditioned on DRB1*15:01, DRB1*15:01 presence, DRB1*15:01
homozygotes and interaction term between presence of DRB1*15:01 and
DQA1*01:01 were included.
The genotyping on SWE cohort was carried out using MS replication chip, a
custom-made Illumina chip with 19,000 markers in the extended HLA region.
Related individuals (n= 26) and population outliers (n= 10) were identiﬁed as
described for the SCAND cohort. Three PCA vectors were signiﬁcant and used for
correcting population stratiﬁcation. HLA imputation and statistical analysis was
performed in the same way as for the SCAND cohort.
The German cohort was genotyped using Illumina Omni-family microarrays.
Detailed characterization and quality control of the German cohort has been
published previously9 (as cohort DE1 within the referenced publication). HLA
alleles were imputed from genotype data using HIBAG v1.6.075. Alleles with a
posterior probability >0.5 were converted to hard calls. Results were validated using
available HLA typing of 442 patients from the same cohort. SNPs were imputed
with SHAPEIT2 and IMPUTE2, using the 1000 Genomes Phase 1 June 2014
release as a reference panel. Conditional regression analyses were conducted in
R 3.3, using imputed HLA allele counts and imputed SNP dosage data. To control
for population substructure, sex and the ﬁrst eight multidimensional scaling
components of the genetic similarity matrix were included as covariates in the
regression model.
The Icelandic samples were genotyped at deCODE genetics using Illumina
HumanHap610, HumanHap660, Omni-1, HumanHap300, HumanCNV30,
HumanHap1M, Omni2.5, or Omni Express bead chips and additional genotypes were
derived by long-range phasing and imputation76,77. The Icelandic HLA genotype
calling was performed using Graphtyper78. Graphtyper constructs a pangenome
graph for each HLA gene, in which each known HLA allele is represented with a path
in the graph. Illumina short-read sequences are then aligned to the pangenome graphs
and on the basis of the graph alignments, HLA alleles are genotyped. Subsequently,
the HLA allele genotypes were imputed76. Association testing was performed using
logistic regression and p-values were corrected for population stratiﬁcation using the
method of genomic control. The correction factor was estimated as 1.127 by
association testing of 10,000 randomly selected sequence variants from all over the
genome.
Both random and ﬁxed effects meta-analysis between the SCAND, SWE, DE,
and ICE cohorts were carried out using the meta-analysis command in PLINKv1.9.
Forest plots were generated in the rmeta package.
Data availability. The 450K array data from monocytes and whole blood are
available in the Gene Expression Omnibus (GEO) database under accession
number GSE43976 and GSE106648, respectively. The RNA-seq data from PBMCs
used for analyses is provided in Supplementary Data 8. The RNA-seq data could
not be deposited due to inconsistencies in the current routines regarding data
processing agreements, but will be made available from the corresponding author
upon request and signature of data transfer agreement. The case-control cohort
data used for association analysis will be made available from the corresponding
author upon request and upon signature of data transfer agreement. The Twingene
data can be accessed through application to the Twingene study coordinators. The
raw genotype data of the German dataset cannot be shared for privacy reasons.
Aggregated summary statistics are available upon request. Summary level data
from deCODE may be provided by the PI upon reasonable request.
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